BiotechTube

LBH589 + Epoetin Alfa

Phase 2Terminated
0 watching 0 views this week⚡ Active
52
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Myelodysplastic Syndrome (MDS)

Conditions

Myelodysplastic Syndrome (MDS)

Trial Timeline

Nov 1, 2009 → Aug 1, 2012

NCT ID
NCT01034657

About LBH589 + Epoetin Alfa

LBH589 + Epoetin Alfa is a phase 2 stage product being developed by Novartis for Myelodysplastic Syndrome (MDS). The current trial status is terminated. This product is registered under clinical trial identifier NCT01034657. Target conditions include Myelodysplastic Syndrome (MDS).

Hype Score Breakdown

Clinical
17
Activity
12
Company
10
Novelty
5
Community
5

Clinical Trials (1)

NCT IDPhaseStatus
NCT01034657Phase 2Terminated

Competing Products

20 competing products in Myelodysplastic Syndrome (MDS)

See all competitors
ProductCompanyStageHype Score
NEX-18a injection + Azacitidine InjectionNanexa ABPhase 1
28
JSP191Jasper TherapeuticsPhase 1
25
Humanized anti-CD117 Monoclonal Antibody (JSP191)Jasper TherapeuticsPhase 1
25
GTB-3550 TriKE® Phase I + GTB-3550 TriKE® Phase IIGT BiopharmaPhase 1/2
33
Erlotinib HydrochlorideAstellas PharmaPhase 2
52
Decitabine + Decitabine + DecitabineEisaiPhase 2
52
Decitabine + Valproic AcidEisaiPhase 2
52
decitabine + decitabineEisaiPhase 2
52
decitabine + azacitidineEisaiApproved
85
DecitabineEisaiPhase 2
52
decitabine + decitabine + decitabine + decitabineEisaiPhase 1
33
Decitabine, Arsenic Trioxide and Ascorbic AcidEisaiPhase 2
52
Subcutaneous DecitabineEisaiPhase 1
33
DecitabineEisaiPhase 2
52
Galunisertib + PlaceboEli LillyPhase 2/3
65
DSP-7888Sumitomo PharmaPhase 1/2
41
TP-0184Sumitomo PharmaPhase 1/2
41
DecitabineJohnson & JohnsonPhase 2
52
Epoetin alfaJohnson & JohnsonPhase 2
52
ZARNESTRA, tipifarnib, R115777Johnson & JohnsonPhase 2
52

Other Products from Novartis

LCZ696Approved
85
zoledronic acidApproved
85
NateglinideApproved
85
TenofovirApproved
85
FTY720Approved
85